1. The median progression-free survival for trametinib was significantly greater than that for standard-of-care therapy (13 months vs. 7.2 months). ...
1. Both CA125 serum and transvaginal ultrasound annual screening did not significantly reduce deaths due to ovarian or tubal cancer ...
1. Adavosertib plus gemcitabine showed improved progression-free and overall survival in platinum-resistant or refractory recurrent ovarian cancer versus gemcitabine plus ...
Recent advances have been demonstrated with the administration of intraperitoneal (IP) cisplatin and paclitaxel, where women with stage III ovarian ...
Screening for breech presentation using universal late-pregnancy ultrasonography: A prospective cohort study and cost effectiveness analysis Fetal presentation has long ...
